Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection.

Abstract

In many regions where soil-transmitted helminth infections are endemic, single-dose albendazole is used in mass drug administration programs to control infections. There are little data on the efficacy of the standard single-dose administration compared to that of alternative regimens. We conducted a randomized, controlled, assessor-blinded clinical trial to determine the efficacies of standard and extended albendazole treatment against soil-transmitted helminth infection in Gabon. A total of 175 children were included. Adequate cure rates and egg reduction rates above 85% were found with a single dose of albendazole for Ascaris infection, 85% (95% confidence interval [CI], 73, 96) and 93.8% (CI, 87.6, 100), respectively, while two doses were necessary for hookworm infestation (92% [CI, 78, 100] and 92% [CI, 78, 100], respectively). However, while a 3-day regimen was not sufficient to cure Trichuris (cure rate, 83% [CI, 73, 93]), this regimen reduced the number of eggs up to 90.6% (CI, 83.1, 100). The rate ratios of two- and three-dose regimens compared to a single-dose treatment were 1.7 (CI, 1.1, 2.5) and 2.1 (CI, 1.5, 2.9) for Trichuris and 1.7 (CI, 1.0, 2.9) and 1.7 (CI, 1.0, 2.9) for hookworm. Albendazole was safe and well tolerated in all regimens. A single-dose albendazole treatment considerably reduces Ascaris infection but has only a moderate effect on hookworm and Trichuris infections. The single-dose option may still be the preferred regimen because it balances efficacy, safety, and compliance during mass drug administration, keeping in mind that asymptomatic low-level helminth carriage may also have beneficial effects. (This study has been registered at ClinicalTrials.gov under registration number NCT01192802.).

• Authors: Ayola A Adegnika, Jeannot F Zinsou, Saadou Issifou, Ulysse Ateba-Ngoa, Roland F Kassa, Eliane N Feugap, Yabo J Honkpehedji, Jean-Claude Dejon Agobe, Hilaire M Kenguele, Marguerite Massinga-Loembe, Selidji T Agnandji, Benjamin Mordmüller, Michael Ramharter, Maria Yazdanbakhsh, Peter G Kremsner, Bertrand Lell
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 58 Issue 5 Pg. 2535-40 (May 2014) ISSN: 1098-6596 [Electronic] United States
• PMID: 24550339 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anthelmintics
• Albendazole

Topics

• Adolescent
• Albendazole (administration & dosage, therapeutic use)
• Ancylostomatoidea (drug effects, pathogenicity)
• Animals
• Anthelmintics (administration & dosage, therapeutic use)
• Ascariasis (drug therapy)
• Ascaris lumbricoides (drug effects, pathogenicity)
• Child
• Child, Preschool
• Female
• Hookworm Infections (drug therapy)
• Humans
• Infant
• Male
• Trichuriasis (drug therapy)
• Trichuris (drug effects, pathogenicity)